Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

(MedPage Today) -- In the wake of a surprise FDA advisory committee vote on Thursday, the third time could be the charm for RP1 (vusolimogene oderparepvec), a melanoma drug candidate that's already been rejected twice by the agency.
Despite doubts...